Plans scrapped for Xadago trial for levodopa-induced dyskinesia
Newron Pharmaceuticals and Zambon Pharma have ended their plans to run a clinical trial to test Xadago (safinamide) for…
Articles by Marisa Wexler, MS
Alpha-synuclein buildup seen in vagus nerve in prodromal disease
Overproduction of toxic forms of the alpha-synuclein protein — a Parkinson’s disease hallmark — in the vagus nerve, the longest…
Selonterra awarded $2.5M for Parkinson’s genetics therapies
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $2.5 million grant to Selonterra to support…
Student-led startup working on way to help Parkinson’s patients write
SteadyScrib, a startup company led by undergraduate students at Northwestern University, is working on a pen-and-clipboard system that…
Fatty molecule may mark treatment efficacy with common mutations
Levels of a fatty molecule called Bis(monacylglycerol) phosphate, or BMP, are significantly elevated in the urine of people with certain…
Cholesterol-lowering drug aids mitochondria in Parkinson’s models
Probucol, a cholesterol-lowering medication previously used in Western countries, improved motor function and lengthened the lifespan of treated animals in…
Inflammation elevated in brains of newly diagnosed patients
Inflammation in the brain is detectable at the earliest stages of Parkinson’s disease and even before treatment is begun,…
GFAP protein levels may help predict dementia risk in Parkinson’s
Levels of the GFAP protein in blood are significantly higher in Parkinson’s disease patients with cognitive impairment — particularly…
Izar device trains hand function in neurological disease
A new device called Izar that aims to help assess and train hand function for people with neurological disorders such…
Cerevance gains $51M in new funding, will launch trial of CVN424
Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test…